Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
52,953 Cancer
clinical trials

Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Albany Medical Center
mi
from
Albany, NY
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
University Medical Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Advocate Children's Hospital, Park Ridge
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Madigan Army Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Musculoskeletal, Oncology Clinical Trial
Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection
Status: Enrolling, Phase III
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma Clinical Trial
Docetaxel and Capecitabine in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling, Phase II
Updated: 12/31/1969
Great Plains Health (Callahan Cancer Center)
mi
from
North Platte, NE
Click here to add this to my saved trials
Cancer Clinical Trial
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling, Phase I
Updated: 12/31/1969
GSK Investigational Site
mi
from
Duarte, CA
Click here to add this to my saved trials
Cancer Clinical Trial
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling, Phase I
Updated: 12/31/1969
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Oncology Clinical Trial
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Status: Enrolling, Phase I, II
Updated: 4/30/2018
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Methoxyamine, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
Status: Enrolling, Phase I
Updated: 12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
New Jersey Hematology Oncology Associates
mi
from
Brick, NJ
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Fort Belvoir Community Hospital
mi
from
Fort Belvoir, VA
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Gwinnett Medical Center - Center for Cancer Care
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
St. Joseph's Hospital
mi
from
Lexington, KY
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Mercy Physicians of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Florida Cancer Research Institute
mi
from
Plantation, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Central Coast Medical Oncology
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Oncology Clinical Trial
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Solid Tumors Clinical Trial
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
University Cancer and Blood Center LLC
mi
from
Athens, GA
Click here to add this to my saved trials
Solid Tumors Clinical Trial
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Solid Tumors Clinical Trial
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Click here to add this to my saved trials
Solid Tumors Clinical Trial
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Solid Tumors Clinical Trial
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Oncology Consultants
mi
from
Houston, TX
Click here to add this to my saved trials
Solid Tumors Clinical Trial
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Oncology, Other Clinical Trial
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Status: Enrolling, Phase
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Penrose Cancer Center
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KS
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Tennessee Health Science Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Intermountain Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Memorial Health University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Renal Cell Carcinoma Clinical Trial
Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Status: Enrolling, Phase I
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Endocrine Response in Women With Invasive Lobular Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Endocrine Response in Women With Invasive Lobular Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Prostate Cancer Clinical Trial
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
Status: Enrolling, Phase I
Updated: 3/1/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Gastroenterology, Nephrology / Urology, Oncology Clinical Trial
Physical Therapy for Men Undergoing Prostatectomy
Status: Enrolling
Updated: 9/22/2015
IU Health Methodist Hospital and IU Health University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Status: Enrolling, Phase III
Updated: 12/31/1969
The Center for Cancer and Blood Disorders (Regional Cancer Care Associates LLC)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Status: Enrolling, Phase III
Updated: 12/31/1969
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Status: Enrolling, Phase III
Updated: 12/31/1969
Hunterdon Medical Center
mi
from
Flemington, NJ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Status: Enrolling, Phase III
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Status: Enrolling, Phase III
Updated: 12/31/1969
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Kansas Cancer Center
mi
from
Westwood, KS
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
University of Vermont College of Medicine
mi
from
Burlington, VT
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Mary Greeley Medical Center
mi
from
Ames, IA
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Kaiser Permanente - Anaheim
mi
from
Anaheim, CA
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Alaska Breast Care and Surgery LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Randolph Hospital
mi
from
Asheboro, NC
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
PeaceHealth Saint Joseph Medical Center
mi
from
Bellingham, WA
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Strecker Cancer Center-Belpre
mi
from
Belpre, OH
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Sanford Clinic North-Bemidgi
mi
from
Bemidji, MN
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Central Vermont Medical Center/National Life Cancer Treatment
mi
from
Berlin, VT
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Saint Luke's University Hospital-Bethlehem Campus
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Saint Vincent Healthcare
mi
from
Billings, MT
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Sanford Bismarck Medical Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
CoxHealth Cancer Center
mi
from
Branson, MO
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Montefiore Medical Center-Weiler Hospital
mi
from
Bronx, NY
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Fairview Ridges Hospital
mi
from
Burnsville, MN
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Southeast Cancer Center
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Charleston Hematology Oncology Associates PA-St. Francis
mi
from
Charleston, SC
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Bethesda North Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Good Samaritan Hospital - Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Southeastern Medical Oncology Center-Clinton
mi
from
Clinton, NC
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Mercy Cancer Center - West Lakes
mi
from
Clive, IA
Click here to add this to my saved trials
Oncology Clinical Trial
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 4/9/2018
Billings Clinic-Cody
mi
from
Cody, WY
Click here to add this to my saved trials